A Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors

Status
Active
Cancer Type
Multiple Primaries
Trial Phase
Phase I
Eligibility
18 and over, Male and Female
Study Type
Biomarker/Laboratory analysis
Treatment
NCD ID
NCT01473095
Protocol IDs
ARQ 092-101 (primary)
Study Sponsor
ArQule, Incorporated

Summary

This is an open-label, Phase 1, dose escalation study of oral ARQ 092 administered to subjects with advanced solid tumors. The study is designed to explore the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARQ 092 and to define a recommended Phase 2 dose of ARQ 092.